Thermo Fisher Scientific’s new RNA Control product will enable the validation of Covid-19 molecular diagnostic tests. Credit: Thermo Fisher Scientific Inc.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Thermo Fisher Scientific has launched AcroMetrix Coronavirus 2019 (Covid-19) RNA Control to monitor and validate Covid-19 molecular diagnostic tests.

The new quality control product is developed by formulating synthetic RNA transcripts that contain unique N, S, E and Orf1ab regions of SARS-CoV-2 genome into a proprietary buffer.

Thermo Fisher’s latest product launch is aimed at fighting the coronavirus outbreak.

As necessary for the test, the RNA is set for reverse transcription, PCR amplification and detection.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The kit contains two SARS-CoV-2 specific RNA vials at the concentration that will result in low-positive and ultra-low positive in commonly used Covid-19 nucleic acid testing methods that are based on Polymerase Chain Reaction (PCR).

Thermo Fisher speciality diagnostics business senior vice-president and president Gianluca Pettiti said: “Our team is committed to providing innovative solutions to support our customers with better diagnostic tools.

“The AcroMetrix Coronavirus 2019 (Covid-19) RNA Control is a positive control to aid in validating and monitoring Covid-19 diagnostic tests.”

The new RNA control is available as a Research Use Only (RUO) product globally and is not intended for clinical use.

Last month, the company announced that it expects to produce up to five million testing kits during April, to detect nucleic acid from the SARS-CoV-2 virus that causes Covid-19 disease.

Currently, the company has 1.5 million tests available to ship under the emergency use authorisation (EUA) label.

The test runs on Applied Biosystems TaqPath Assay technology and delivers patient results within four hours from when a lab receives a sample.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact